Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment

被引：0
|
作者：
Lichtenstein, Gary R. [1 ]
Loftus, Edward V., Jr. [2 ]
Bloom, Stuart [3 ]
Lawendy, Nervin [4 ]
Chan, Gary [4 ]
Friedman, Gary S. [4 ]
Zhang, Haiying [4 ]
Wang, Wenjin [4 ]
Thorpe, Andrew J. [4 ]
Nduaka, Chudy I. [4 ]
Su, Chinyu [4 ]
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
[4] Pfizer Inc, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2018年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
571
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [31] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Curtis, Jeffrey R.
    Wood, Susan P.
    Soma, Koshika
    Nduaka, Chudy I.
    Benda, Birgitta
    Gruben, David
    Nakamura, Hiroyuki
    Komuro, Yoshihiro
    Zwillich, Samuel H.
    Wang, Lisy
    Riese, Richard J.
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 837 - 852
  • [32] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
    Baker, Milton
    Chalabi, Youb
    Genovese, Mark
    Taylor, Peter
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    Keystone, Edward
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505
  • [33] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 24 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTERIM DATA FROM OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 682 - 682
  • [34] Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response
    Panaccione, Remo
    Abreu, Maria T.
    Lazariciu, Irina
    Mundayat, Rajiv
    Lawendy, Nervin
    Salese, Leonardo
    Woolcott, John C.
    Sands, Bruce E.
    Chaparro, Maria
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S351 - S352
  • [35] Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN in Remission or With a Clinical Response
    Panaccione, Remo
    Abreu, Maria T.
    Lazariciu, Irina
    Mundayat, Rajiv
    Lawendy, Nervin
    Salese, Leonardo
    Woolcott, John C.
    Sands, Bruce E.
    Chaparro, Maria
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S351 - S351
  • [36] Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open
    Panaccione, Remo
    Abreu, Maria T.
    Lazariciu, Irina
    Mundayat, Rajiv
    Lawendy, Nervin
    Salese, Leonardo
    Woolcott, John C.
    Sands, Bruce E.
    Chaparro, Maria
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (12) : 1534 - 1544
  • [37] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Fleishaker, Dona
    Wang, Cunshan
    Kudlacz, Elizabeth
    Menon, Sujatha
    Fallon, Lara
    Hendrikx, Thijs
    Kanik, Keith S.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [38] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE SECOND INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S109 - S109
  • [39] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Fleishaker, Dona
    Wang, Cunshan
    Kudlacz, Elizabeth
    Menon, Sujatha
    Hendrikx, Thijs
    Kanik, Keith S.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [40] Laboratory Parameters Related to Monitoring in Patients With Ulcerative Colitis Treated With Tofacitinib for up to 3 Years in the OCTAVE Open-Label, Long-Term Extension Study
    Melmed, Gil Y.
    Chang, Shannon
    Kulisek, Nicole
    Fan, Haiyun
    Lawendy, Nervin
    Maller, Eric
    Soonasra, Arif
    Irving, Peter M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S431 - S431
12345